NasdaqGS:IONS
NasdaqGS:IONSBiotechs

How Investors Are Reacting To Ionis Pharmaceuticals (IONS) Raising Revenue Guidance and Narrowing Losses

Ionis Pharmaceuticals reported third-quarter 2025 results, with revenue rising to US$156.72 million and net loss narrowing to US$128.61 million compared to the prior year; the company also raised its full-year revenue guidance to a range of US$875 million to US$900 million, above previous expectations. Management signaled increased investment in commercial preparations for upcoming therapies, highlighting confidence in the company's late-stage pipeline and anticipated product launches next...
NasdaqGS:HAS
NasdaqGS:HASLeisure

Hasbro’s Valuation After New Partnership and 36% Share Price Run in 2025

Are you wondering whether Hasbro’s recent run-up means the stock is a hidden gem, or if there’s more to the story beneath the surface? After climbing 36.2% year-to-date, Hasbro’s share price has outpaced many of its peers, with a notable 26.2% gain over the past 12 months, even while seeing a modest dip of 1.4% this week. These price moves have coincided with the company making headlines for a new partnership deal that could broaden its entertainment reach, along with a sale of non-core...
NasdaqGS:APLD
NasdaqGS:APLDIT

AI Data Center Power Deal Could Be a Game Changer for Applied Digital (APLD)

Babcock & Wilcox recently announced an agreement with Applied Digital to design and build a US$1.5 billion, one-gigawatt power plant complex supporting Applied's AI data center expansion, with operations expected to begin in 2028. Securing such large-scale, long-term infrastructure partnerships signals Applied Digital's strengthening position as a major enabler of next-generation AI data center growth in North America. Now, we'll explore how this major infrastructure buildout and long-term...
NYSE:TOST
NYSE:TOSTDiversified Financial

Toast (TOST) Profitability Surges, Challenging Cautious Valuation Narratives with 40% Annual Earnings Growth

Toast (TOST) marked a major milestone over the last year as it transitioned to profitability, with earnings climbing at a remarkable 40.2% annual rate over the past five years. Net profit margins also improved, and forecasts now call for earnings to grow 26.4% per year, well ahead of the broader US market’s 15.8% pace. With revenue expected to increase 14.8% annually, Toast looks set for significant near-term profit growth. However, its lofty 101.6x price-to-earnings ratio could raise...
NYSE:COMP
NYSE:COMPReal Estate

Compass (COMP): Examining Valuation After Recent 15% Share Price Climb

Compass (COMP) shares have seen a steady climb over the past month, with the stock up about 15%. Investors are paying close attention to where the market is valuing this real estate platform given its recent performance. See our latest analysis for Compass. Compass's 15% one-month share price return continues a year-to-date climb of over 51%, with total shareholder return for the past three years soaring well past 375%. The recent momentum signals growing optimism around Compass’s growth...
NYSE:GOLF
NYSE:GOLFLeisure

Acushnet’s (GOLF) Quarterly Profit Dip and Strong Sales Might Change the Case for Investing

Acushnet Holdings Corp. recently announced third-quarter 2025 earnings, reporting sales of US$657.66 million, up from US$620.5 million last year, while net income decreased to US$48.51 million from US$56.22 million over the same period. An insightful detail is that despite the quarterly profit dip, the company achieved higher nine-month sales and net income compared to the prior year, highlighting year-to-date operational resilience. We'll explore how Acushnet's higher year-to-date sales,...
NasdaqGS:MRNA
NasdaqGS:MRNABiotechs

A Look at Moderna (MRNA) Valuation After Key Oncology Trial Milestone and Recent Setbacks

Moderna (MRNA) drew attention after announcing it had dosed the first patient in a Phase 1/2 trial of mRNA-2808, its experimental T-cell engager for relapsed or refractory multiple myeloma. This development comes as investors weigh the company’s evolving strategy amid recent revenue declines and a late-stage vaccine setback. See our latest analysis for Moderna. Despite the buzz around its latest oncology milestone, Moderna’s short-term momentum has faded as headwinds from a failed late-stage...
NasdaqGS:FLEX
NasdaqGS:FLEXElectronic

A Fresh Look at Flex (FLEX) Valuation Following This Year’s 69% Share Price Climb

Flex (FLEX) shares have moved steadily in recent sessions, drawing attention from market watchers interested in the tech manufacturing space. Investors are weighing what the company’s stock performance may signal about its long-term earnings potential. See our latest analysis for Flex. Flex’s share price has surged 68.98% so far this year, and its 1-year total shareholder return of 67.42% shows that momentum has been building over both the short and long term. A strong 31.28% share price...
NasdaqGM:GCMG
NasdaqGM:GCMGCapital Markets

GCM Grosvenor (GCMG): Is the Stock Undervalued After Recent Share Price Fluctuations?

GCM Grosvenor (GCMG) has seen its stock fluctuate over the past month, with a slight decline of roughly 2 percent, even as the company has maintained steady revenue growth. Investors might be watching for catalysts that could shift momentum. See our latest analysis for GCM Grosvenor. Zooming out, GCM Grosvenor's share price has been fairly stable compared to some peers. However, the one-year total shareholder return of -1.77 percent points to fading momentum lately, despite a solid 59.9...
NasdaqGS:BSY
NasdaqGS:BSYSoftware

Bentley Systems (BSY) Margin Decline Sparks Debate Over Valuation Premiums and Growth Narratives

Bentley Systems (BSY) posted a net profit margin of 17.9%, down from last year’s 29.2%, with the company’s earnings showing negative growth relative to the prior year after averaging 24.2% annual growth over the past five years. The share price currently stands at $48.48, which is above some fair value estimates. Ongoing forecasts suggest earnings will grow 14.9% per year and revenue will grow 8.6% per year, both trailing the broader US market. Margins compressed during this period, but...
NasdaqGM:NUAI
NasdaqGM:NUAIOil and Gas

Assessing New Era Energy & Digital (NUAI) Valuation Following Sustainability Initiatives and Texas Data Center Progress

On November 4, New Era Energy & Digital (NUAI) shared updates in its Q4 2025 investor presentation and unveiled strategic moves toward sustainability. The company detailed progress on its Texas Critical Data Centers project and emphasized efforts to improve power reliability. See our latest analysis for New Era Energy & Digital. Momentum has surged for New Era Energy & Digital, with a 1-month share price return of nearly 217% and a massive 1,366% rise over the last 90 days, following its...
NasdaqGS:GFS
NasdaqGS:GFSSemiconductor

How GlobalFoundries’ (GFS) Dresden Expansion and Silicon Labs Deal Could Shape Its Manufacturing Future

In late October 2025, GlobalFoundries and Silicon Labs announced the expansion of their partnership to develop next-generation, energy-efficient wireless technologies, while GlobalFoundries also unveiled a plan to invest EUR 1.1 billion to significantly expand its Dresden, Germany wafer manufacturing site by 2028, supported by government incentives. These moves reflect rising demand for secure, low-power IoT and wireless chips, and highlight GlobalFoundries’ efforts to strengthen supply...
NYSE:CF
NYSE:CFChemicals

How Investors Are Reacting To CF Industries (CF) Surging Q3 Sales and Earnings Growth

CF Industries Holdings, Inc. recently reported third quarter and nine-month results for 2025, showing sales of US$1.66 billion and net income of US$353 million for the quarter, both rising compared to the same period last year. An interesting aspect of this report is the continued growth in earnings per share from continuing operations, reaching US$2.19 for the quarter and US$6.39 year-to-date, reflecting improved operational efficiency and financial performance. We'll examine how this...
NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

Is Viking’s (VKTX) Upcoming VK2735 Data Release Shifting Its Position in Obesity Drug Innovation?

Viking Therapeutics announced it will present new clinical data on its dual GLP-1/GIP agonist VK2735, currently under evaluation in both injectable and oral forms for obesity and type 2 diabetes, at ObesityWeek 2025 in Atlanta and additional healthcare conferences in November. This focus on advancing late-stage clinical programs and sharing results at major scientific forums highlights Viking’s growing presence in the competitive obesity treatment landscape. We’ll explore how Viking’s...
NYSE:DBD
NYSE:DBDTech

Diebold Nixdorf (DBD): Deep Discount to Fair Value Reinforces Optimistic Turnaround Narrative

Diebold Nixdorf (DBD) remains unprofitable, but losses have narrowed significantly over the last five years at an annual rate of 41%. The company is expected to grow earnings at 36.43% per year, with a return to profit forecast within three years. This pace is well above the broader market. Revenue growth is projected at a slower 3% per year, which may not excite those hunting for top-line acceleration. However, current valuation metrics like a 0.6x price-to-sales ratio and trading well below...
NasdaqGS:MYGN
NasdaqGS:MYGNBiotechs

Myriad Genetics (MYGN): Losses Compound at 21.1% Annually, Undercutting Value Narrative

Myriad Genetics (MYGN) remains in the red, with losses having climbed at a 21.1% annualized rate over the past five years, and the company is expected to stay unprofitable for at least the next three years. While revenue is forecast to grow 4.5% per year, which is less than half the 10.5% broader US market expectation, shares currently trade at $6.58, below an estimated fair value of $9.83. Despite a low price-to-sales ratio of 0.7x, ongoing net losses and a slower revenue trajectory continue...
NasdaqCM:SGML
NasdaqCM:SGMLMetals and Mining

Will Analyst Skepticism Around Sigma Lithium's (SGML) Earnings Shift Views on Management Credibility?

Sigma Lithium Corporation is preparing to release its earnings report on November 14, 2025, amid heightened anticipation due to mixed analyst expectations of growing revenues but ongoing negative earnings per share. The company's recent downgrade to Zacks Rank #5 (Strong Sell) has prompted greater scrutiny of its near-term outlook, particularly as these shifts contrast with broader market gains. We'll now explore how heightened analyst skepticism ahead of the earnings announcement may affect...
NYSE:AEM
NYSE:AEMMetals and Mining

Agnico Eagle Mines (NYSE:AEM): Fresh Results and Confident Guidance Spark New Valuation Debate

Agnico Eagle Mines (NYSE:AEM) just posted some eye-catching quarterly results, with strong year-over-year gains in both net income and earnings per share. The company also chose to reaffirm its full-year gold production guidance, which signals operational consistency and management’s positive outlook. See our latest analysis for Agnico Eagle Mines. There’s been no shortage of headlines for Agnico Eagle Mines lately, with standout earnings, a steady dividend, and ongoing share buybacks all...
NYSE:ZIM
NYSE:ZIMShipping

How Earnings Forecasts and Revenue Outlook May Reshape the Investment Case for ZIM (ZIM)

ZIM Integrated Shipping Services recently saw its shares fall behind the broader market, as investors focused on the company's upcoming November 20, 2025, earnings report and the outlook for a significant decrease in earnings and revenue from the previous year. While analysts have modestly raised consensus EPS estimates, ZIM's forward P/E ratio remains well below industry norms and the broad analyst view remains cautious, reflecting concerns over the company's near-term earnings power. With...
NYSE:LUCK
NYSE:LUCKHospitality

Lucky Strike Entertainment (LUCK): Losses Narrowed 44% Annually, Profit Forecast Sets Up Narrative Test

Lucky Strike Entertainment (LUCK) narrowed its losses at a swift 44% annual rate over the past five years and is now forecast to swing into profitability within the next three years. Analysts expect earnings to accelerate at 107.07% per year, even as revenue growth is set to lag the wider US market at 5.1% per year. With a current share price of $7.98 that sits significantly below an estimated fair value of $30.48, the company’s ongoing progress toward profit and attractive valuation have...
NYSE:NFG
NYSE:NFGGas Utilities

National Fuel Gas (NFG): Assessing Valuation After Strong Earnings Turnaround and Return to Profitability

National Fuel Gas (NFG) just posted its fourth quarter earnings, revealing a marked shift from last year’s net loss to a net income of $107 million. Revenue climbed to $456 million, which was up sharply from the prior year. See our latest analysis for National Fuel Gas. After this dramatic earnings turnaround, National Fuel Gas shares are holding steady near $79.40, marking a 29.4% gain for the year so far. Long-term investors have also been well rewarded, with a five-year total shareholder...
NYSE:PAGS
NYSE:PAGSDiversified Financial

How PagSeguro's Stock Rally and Regulatory News Impact Its 2025 Valuation

Wondering if PagSeguro Digital’s stock is actually a hidden value play or just another tech name riding the market momentum? Let's dig into what truly drives its current price tag. PagSeguro’s shares have been on the move, climbing 1.4% in the past week, 4.7% over the last month, and an impressive 50.2% year-to-date. Over longer periods, though, returns are mixed, with a 22.1% gain in the past year but steep drops when you look back three and five years. Several headlines have shaped...
NYSE:NVO
NYSE:NVOPharmaceuticals

Does Novo Nordisk’s 44% Stock Slide Signal a New Opportunity in 2025?

Ever wondered if Novo Nordisk is still a bargain or if the market has already priced in its strengths? Here is a breakdown of what has been happening and what the numbers really say. After some impressive long-term gains, Novo Nordisk’s stock jumped more than 50% over the past five years but has pulled back sharply, falling 18.8% in the past month and down over 44% year-to-date. The latest headlines have shifted focus to Novo Nordisk’s expanding diabetes and obesity...
NasdaqGS:IOSP
NasdaqGS:IOSPChemicals

Innospec (IOSP) Profit Margin Drop Challenges Bullish Narratives Despite DCF Undervaluation

Innospec (IOSP) reported a net profit margin of 1.1%, sharply down from 7.9% a year ago, highlighting a notable drop in profitability over the last twelve months. The company’s earnings contracted compared to its five-year trend, though its long-term record still shows 6.7% average annual earnings growth over the past five years. While high quality of earnings is maintained, the most recent results put investors in a spot as they balance fading margins and negative near-term earnings growth...